Tirzepatide denied as not medically necessary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for tirzepatide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Tirzepatide on Medical-Necessity Grounds

Blue Cross Blue Shield's medical-necessity denials for tirzepatide most commonly arise when the submitted prior authorization or appeal documentation does not fully satisfy the eligibility criteria in BCBS's current clinical coverage policy. BCBS medical-necessity criteria for tirzepatide typically address the patient's diagnosis, the severity of that condition as reflected in the medical record, the history of prior treatment, and comorbid conditions that affect clinical decision-making. A gap in any of these areas — even one undocumented requirement — is sufficient for denial.

Because BCBS operates as a network of regional plans, the specific criteria may vary by state plan. Always obtain the exact clinical policy document from your specific BCBS plan, not a national template.

## Your Federal Appeal Rights

• ACA §2719 / External Review: After exhausting BCBS's internal appeal process, you may request external review by a certified IRO. The request window is typically around four months from the final internal denial date — confirm the exact deadline from your denial letter.
• ERISA §503 Full-and-Fair Review: ERISA-governed plans must provide you with the specific criteria applied in the denial and must consider new clinical evidence submitted on appeal.
• State Prompt-Payment and Utilization Review Laws: Many states impose additional requirements on BCBS plans, including maximum turnaround times and standards for reviewer qualifications. Check your state insurance department's rules.
• Expedited Review: Available when clinical urgency is present; request it simultaneously with the standard appeal.

## Appeal Timeline

1. Request your regional BCBS plan's current clinical policy for tirzepatide and the specific denial rationale. 2. Identify every unmet criterion in the denial letter and work with your prescriber to address each one. 3. File the internal appeal with complete documentation within the timeframe in your denial letter. 4. If denied, request external review before the deadline — IROs apply an independent clinical standard.

## Documentation to Gather

• Diagnosis confirmation: ICD-coded diagnosis from the treating physician supported by objective clinical findings in the chart (labs, vitals, clinical notes).
• Clinical severity documentation: Chart notes, lab trends, imaging, and specialist records demonstrating the severity of the condition and its clinical impact on the patient.
• Prior treatment history: A complete, dated record of every prior therapy BCBS's policy requires — including drug name, start and stop dates, dosing, and outcome (inadequate response, adverse effect, clinical contraindication).
• Comorbidity documentation: Records of all weight-related or metabolic comorbidities that are relevant to BCBS's criteria.
• Prescriber medical-necessity letter: A detailed letter specifically addressing each of BCBS's policy criteria by name, citing the relevant chart entry for each.

## Criteria-Mapping Structure

Build the appeal as a structured, requirement-by-requirement response. Reproduce each criterion from BCBS's policy verbatim in the left column of a table. In the right column, cite the specific chart document — with date and author — that satisfies that criterion. Where the chart is silent on a required element, coordinate with the prescriber to add a clinical note before filing. A complete mapping leaves the reviewer no basis for a second denial on documentation grounds, and positions the file for a strong external review if needed.